Preliminary Data From J&J SIRIUS Coated Stent Trial Consistent With RAVEL
This article was originally published in The Gray Sheet
Executive Summary
Data from the first 400 patients in Johnson & Johnson's U.S. SIRIUS trial of the Cypher sirolimus-eluting coronary stent appear consistent with positive European data from the RAVEL trial, despite inclusion of a larger and sicker patient cohort